Bolt Biotherapeutics, Inc. (BOLT): Total Assets
$56.75M
As of 2025-12-31
$40.34M
As of 2026-06-30
-37.1%
3-year compound annual growth
+4.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $56.75M | -43.0% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $99.63M | -37.6% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $159.78M | -29.9% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $227.81M | -26.0% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $307.72M | +561.2% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $46.54M | n/a | 2022-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $56.75M | -43.0% |
| Adagene Inc. (ADAG) | 2025-12-31 | $78.26M | -12.3% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $160.46M | -27.2% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $633.16M | -20.7% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $49.95M | +12.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $150.93M | +63.8% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $5.71B | +5.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $150.83M | +114.5% |
| Immunome Inc. (IMNM) | 2025-12-31 | $683.19M | +184.4% |
Compare BOLT, ADAG, ACRS, XENE side by side · Screen every company in Pharmaceutical Preparations ↗